231 related articles for article (PubMed ID: 18583191)
1. Therapeutic plasma exchange in Casablanca.
Tazi I; Merimi F; Majd A; Benchemsi N
Transfus Apher Sci; 2008 Aug; 39(1):45-8. PubMed ID: 18583191
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic plasma exchange in a single center: Ibni Sina experience.
Arslan O; Arat M; Tek I; Ayyildiz E; Ilhan O
Transfus Apher Sci; 2004 Jun; 30(3):181-4. PubMed ID: 15172620
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.
Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M
Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis.
Kaya E; Keklik M; Sencan M; Yilmaz M; Keskin A; Kiki I; Erkurt MA; Sivgin S; Korkmaz S; Okan V; Doğu MH; Unal A; Cetin M; Altuntaş F; Ilhan O
Transfus Apher Sci; 2013 Jun; 48(3):349-52. PubMed ID: 23619327
[TBL] [Abstract][Full Text] [Related]
5. Plasma exchange in elderly patients.
Basic-Jukic N; Brunetta B; Kes P
Ther Apher Dial; 2010 Apr; 14(2):161-5. PubMed ID: 20438537
[TBL] [Abstract][Full Text] [Related]
6. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective.
Agreda-Vásquez GP; Espinosa-Poblano I; Sánchez-Guerrero SA; Crespo-Solís E; Cabrera-Vásquez S; López-Salmorán J; Barajas J; Peñaloza-Ramírez P; Tirado-Cárdenas N; Velázquez A
J Clin Apher; 2008; 23(5):163-7. PubMed ID: 18819155
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange.
Kankirawatana S; Huang ST; Marques MB
J Clin Apher; 2007; 22(5):265-9. PubMed ID: 17722047
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic apheresis in the Republic of Macedonia - our five years experience (2000-2004).
Milovanceva-Popovska M; Stojkovski Lj; Grcevska L; Dzikova S; Ristovska V; Gogovska L; Polenakovic M
Prilozi; 2006 Jul; 27(1):37-44. PubMed ID: 16862064
[TBL] [Abstract][Full Text] [Related]
9. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
Dada MA; Kaplan AA
Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
[TBL] [Abstract][Full Text] [Related]
10. [10 years plasma exchange with the IBM (Cobe) 2997].
Franz HR; Hohl-Taheri M; Kraatz B; Kühnl P; Neppert J
Beitr Infusionsther; 1990; 26():147-9. PubMed ID: 1703815
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic plasma exchange in Mexico: experience from a single institution.
Lazo-Langner A; Espinosa-Poblano I; Tirado-Cárdenas N; Ramírez-Arvizu P; López-Salmorán J; Peñaloza-Ramírez P; Sánchez-Guerrero SA
Am J Hematol; 2002 May; 70(1):16-21. PubMed ID: 11994977
[TBL] [Abstract][Full Text] [Related]
12. Neurologic indications for therapeutic plasma exchange: an update.
Gwathmey K; Balogun RA; Burns T
J Clin Apher; 2011; 26(5):261-8. PubMed ID: 21915895
[TBL] [Abstract][Full Text] [Related]
13. Trend of indications for therapeutic plasma exchange at an Iranian university hospital.
Shahidi S; Memarzadeh M; Kamali M; Naini AE
Transfus Apher Sci; 2011 Apr; 44(2):119-22. PubMed ID: 21334978
[TBL] [Abstract][Full Text] [Related]
14. The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome.
Sanjay R; Flanagan J; Sodano D; Gorson KC; Ropper AH; Weinstein R
J Clin Apher; 2006 Jul; 21(2):105-10. PubMed ID: 16342192
[TBL] [Abstract][Full Text] [Related]
15. A survey of therapeutic hemapheresis in Norway year 2000.
Taraldsrud E; Kvalheim G; Jørstad S; Stavem K; Aandahl GS
Transfus Apher Sci; 2003 Apr; 28(2):135-41. PubMed ID: 12679117
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters.
Bektas M; Idilman R; Soykan I; Soydan E; Arat M; Cinar K; Coban S; Tuzun A; Bozkaya H; Ormeci N; Ozden A
J Clin Gastroenterol; 2008; 42(5):517-21. PubMed ID: 18344887
[TBL] [Abstract][Full Text] [Related]
17. Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis.
Yamada C; Pham HP; Wu Y; Cooling L; Kim HC; Morgan S; Schwartz J; Winters JL; Wong EC
J Clin Apher; 2017 Feb; 32(1):5-11. PubMed ID: 26946363
[TBL] [Abstract][Full Text] [Related]
18. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
Triantafyllou NI; Grapsa EI; Kararizou E; Psimenou E; Lagguranis A; Dimopoulos A
Ther Apher Dial; 2009 Jun; 13(3):174-8. PubMed ID: 19527462
[TBL] [Abstract][Full Text] [Related]
19. National survey of hemapheresis practice in Hungary 2001-2004.
Belák M; Jákó J
Ther Apher Dial; 2007 Feb; 11(1):22-9. PubMed ID: 17309571
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of pediatric plasma apheresis in intensive care settings.
Haque A; Sher G; Hoda M; Moiz B
Ther Apher Dial; 2014 Oct; 18(5):497-501. PubMed ID: 24674133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
